These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4534 related articles for article (PubMed ID: 29385370)

  • 21. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Wayne AS; Huynh V; Hijiya N; Rouce RH; Brown PA; Krueger J; Kitko CL; Ziga ED; Hermiston ML; Richards MK; Baruchel A; Schuberth PC; Rossi J; Zhou L; Goyal L; Jain R; Vezan R; Masouleh BK; Lee DW
    Haematologica; 2023 Mar; 108(3):747-760. PubMed ID: 36263840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
    Galletta TJ; Rubinstein JD; Krupski C; Nelson AS; Khoury R; Dandoy CE; Davies SM; Phillips CL
    Pediatr Blood Cancer; 2023 May; 70(5):e30271. PubMed ID: 36815392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
    Li N; Li H
    J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
    Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
    Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
    Zuo YX; Jia YP; Wu J; Wang JB; Lu AD; Dong LJ; Chang LJ; Zhang LP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):270-275. PubMed ID: 31104436
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
    Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
    Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
    Pacenta HL; Laetsch TW; John S
    Paediatr Drugs; 2020 Feb; 22(1):1-11. PubMed ID: 31749131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
    Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Pasquini MC; Hu ZH; Curran K; Laetsch T; Locke F; Rouce R; Pulsipher MA; Phillips CL; Keating A; Frigault MJ; Salzberg D; Jaglowski S; Sasine JP; Rosenthal J; Ghosh M; Landsburg D; Margossian S; Martin PL; Kamdar MK; Hematti P; Nikiforow S; Turtle C; Perales MA; Steinert P; Horowitz MM; Moskop A; Pacaud L; Yi L; Chawla R; Bleickardt E; Grupp S
    Blood Adv; 2020 Nov; 4(21):5414-5424. PubMed ID: 33147337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
    Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
    N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Leahy AB; Devine KJ; Li Y; Liu H; Myers R; DiNofia A; Wray L; Rheingold SR; Callahan C; Baniewicz D; Patino M; Newman H; Hunger SP; Grupp SA; Barrett DM; Maude SL
    Blood; 2022 Apr; 139(14):2173-2185. PubMed ID: 34871373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 227.